Prostate Cancer Screening and Prevention
What does screening mean?
Screening means looking for signs of disease in people who have no symptoms. So screening for prostate cancer is looking for early-stage disease when treatment may be more effective. The main screening tools for prostate cancer are the digital rectal examination (DRE) and the prostate-specific antigen (PSA) test. The DRE and PSA test cannot tell if you have cancer; they can only suggest the need for further tests.
What is the DRE?
The DRE or digital (finger) rectal examination is a quick exam for checking the health of the prostate. For this test, the doctor inserts a gloved and lubricated finger into the rectum. This allows the doctor to feel the back portion of the prostate for size and any irregular or abnormally firm areas.
What is the PSA test?
PSA stands for “prostate-specific antigen.” PSA is a substance produced by cells from the prostate gland and released into the blood. The PSA test measures the PSA level in the blood. A small amount of blood is drawn from the arm. The doctor checks the blood to see if the PSA level is normal. The doctor may also use this test to check for any increase in your PSA level compared to your last PSA test.
As a rule, the higher the PSA level in the blood, the more likely a prostate problem is present. But many factors, such as age and race, can affect PSA levels. Some prostate glands produce more PSA than others. PSA levels can also be affected by
Because many factors can affect PSA levels, your doctor is the best person to interpret your PSA test results.
How accurate are the screening tests?
No test is right all the time, and that is true of the PSA test and DRE. The PSA test is better at suggesting that small cancers are present, especially those toward the front or sides of the prostate gland, or deep within it. But the DRE can sometimes help suggest cancers in men with normal PSA levels. That is why both the PSA test and the DRE are usually performed.
If 100 men over age 50 take the PSA test,
After further testing, results will show
What do medical experts say about screening?
Medical experts agree that every man needs balanced information on the pros and cons of prostate cancer screening to help him make an informed decision. Balanced information is important because medical experts disagree about whether men should be screened regularly for prostate cancer.
Medical experts who encourage regular screening believe current scientific evidence shows that finding and treating prostate cancer early, when treatment might be more effective, may save lives. They recommend that all men who have a life expectancy of at least 10 years should be offered the PSA test and DRE annually beginning at age 50. They also recommend offering screening tests earlier to African-American men, and men who have a father or brother with prostate cancer.
Medical experts who do not recommend regular screening want convincing evidence that finding early-stage prostate cancer, and treating it, saves lives. They believe some of these cancers may never affect a man’s health, and treating them could cause temporary or long-lasting side effects like impotence (inability to keep an erection) and incontinence (inability to control the urine flow, resulting in leakage or dribbling). Because they believe it is unclear if the potential benefits of screening outweigh the known side effects of treatment, they recommend that all men be given information on the pros and cons of screening before making their own screening decision.
When will medical experts know more?
Medical experts are working together on major research studies to get answers. These studies are called clinical trials. They will help determine whether a man who gets screened regularly is less likely to die of prostate cancer than a man who does not get screened. Clinical trials involve thousands of male volunteers and take a long time. Results are expected in five to 10 years. They should help experts know if screening for prostate cancer saves lives.
Education / Resources
- American Cancer Society
- National Cancer Institute (NCI)
- National Institutes of Health (NIH)
- National Comprehensive Cancer Network (NCCN)
Prostate Cancer Therapeutics
- Xtandi – Enzalutamide
- Vantas – Histrelin Acetate
- LupronDepot – Leuprolide Acetate for Depot Suspension
- Eligard – Leuprolide Acetate for Injectable Suspension
- Firmagon – Degarelix for Injection
- Xgeva – Denosumab Injection
- Prolia – Denosumab
- Zytiga – Abiratirone
Bladder Cancer Therapeutics